[ad_1]
Chinese Deputy Prime Minister Han Zheng told Macau today that when the country develops a vaccine against covid-19, it will be a “global public good”.
Once China has the vaccine, “it will be made available as a global public good”, guaranteed Han Zheng, at the opening of the International Forum on Science, Technology and Innovation (ISTIF) Conference, held in Macao and organized by the Boao Forum. , known as “Asian Davos”.
The Chinese official also pointed out that when there is a Chinese vaccine, it “means the defeat of covid-19”.
Also in his speech, the Chinese Deputy Prime Minister assured that Beijing wants to collaborate with all countries of the world to control the pandemic, arguing that “together” it will be possible to develop a cure and a vaccine.
These statements in Macau come the day after the Brazilian health authority announced that it had stopped clinical trials of the Coronavac vaccine, by the Chinese laboratory Sinovac, against the new coronavirus, after a “serious” accident with a volunteer.
Coronavac is also being tested in China, Turkey, Bangladesh and Indonesia.
In a statement, the National Health Surveillance Agency (Anvisa) informed that it had decided to stop the clinical trial of the Coronavac vaccine “after the occurrence of a serious adverse event” on 29 October.
Anvisa did not provide further information on the incident, referring only to the fact that the “adverse event” category may include death, potentially fatal side effects, persistent or significant disability or disability, hospitalization or another “clinically significant event”.
“With the interruption of the study, no new volunteers will be able to be vaccinated”, said the agency, adding that “it will evaluate the data observed so far and will judge the risk / benefit of the continuity” of the tests.
The suspension of Coronavac’s clinical trials, involving nine thousand volunteers, came the day after American pharmaceutical giant Pfizer announced that its covid-19 vaccine was 90% effective in testing.
Candidate vaccines from Pfizer and Sinovac are in testing phase 3, the last phase before receiving regulatory approval.
.
[ad_2]
Source link
